文献速递先天性心脏病外科瓣膜外科

Edwards Inspiris Resilia 生物瓣在肺动脉位置的早期令人担忧的结果

Early Concerning Outcomes for the Edwards Inspiris Resilia Bioprosthesis in the Pulmonary Position.
PubMed 文献 · Ann Thorac Surg · 2022-09-27

回顾性分析2019年8月至2021年10月单中心27例肺动脉位置植入Inspiris Resilia生物瓣的患者,中位随访16±8个月,13例(48%)出现新发瓣膜反流,其中6例(22%)进展为中度、3例(11%)为重度,3例(11%)再次行经导管瓣中瓣介入;无早期或晚期死亡。作者认为该瓣膜设计可能不适合低压循环或需改良植入技术。

要点

  • 肺动脉位置植入Inspiris Resilia生物瓣后随访16±8个月,48%患者出现新发反流。
  • 其中22%进展为中度反流、11%为重度反流,11%需再次经导管瓣中瓣介入。
  • 无早期或晚期死亡,无晚期再次手术;标准手术技术植入者出现反流,管道植入者无反流。

核心结论

  • 关于Inspiris Resilia生物瓣用于肺动脉位置的早期数据令人担忧。
  • 该瓣膜设计可能不适合低压循环,或需要改良其植入技术。

研究设计与样本

  • 回顾性分析2019年8月至2021年10月单中心肺动脉位置植入Inspiris Resilia生物瓣的27例患者(15例女性,56%;平均年龄22.26±14.99岁)。

主要发现

  • 最常见原发病为法洛四联症(13例,48%),5例(18.5%)有既往经导管介入史,平均右室舒张末容积指数164.25±45.1 mL/m2。
  • 胸骨切开或再次胸骨切开为最常见入路(21例,77.8%),22例(81.5%)采用标准肺动脉瓣置换技术,5例(18.5%)作为管道植入。
  • 出院时6例(22.2%)存在微量至轻度人工瓣反流;随访期间13例(48%)出现新发人工瓣反流,均采用标准手术技术植入,管道植入病例无反流。
  • 新发反流进展为中度6例(22%)、重度3例(11%),3例(11%)在手术肺动脉瓣置换后行经导管瓣中瓣介入。
  • 无早期死亡,随访完整(平均16±8个月),无晚期死亡或晚期再次手术。

临床怎么用

  • 作者认为Inspiris Resilia生物瓣用于肺动脉位置的早期结果令人担忧,该瓣膜设计可能不适合低压循环,或需改良植入技术。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Inspiris Resilia (Edwards Lifesciences LLC) bioprosthesis has gained widespread use in the aortic position; however no robust data are available about its use in the pulmonary position. METHODS: We reviewed our outcomes for the Inspiris Resilia in the pulmonary position between August 2019 and October 2021. RESULTS: Twenty-seven patients (15 female patients [56%]; mean age, 22.26 ± 14.99 years) were included. The most common original pathology was tetralogy of Fallot (13 patients, 48%). Five patients (18.5%) had prior transcatheter interventions. The mean right ventricular end-diastolic volume index was 164.25 ± 45.1 mL/m2. Sternotomy or repeat sternotomy was the most common approach (21 patients, 77.8%). The standard technique for pulmonary valve replacement was used in 22 patients (81.5%), whereas the prosthesis was implanted as a conduit in the remaining 5 (18.5%). Trivial to mild prosthetic regurgitation was present in 6 patients (22.2%) at the time of discharge. There was no early mortality. Follow-up was complete in all patients (mean, 16 ± 8 months), with no late mortality or late reoperations. New prosthetic regurgitation developed in 13 patients (48%), all of whom underwent replacement with the standard surgical technique. No regurgitation occurred in the conduit cases. This progressed to moderate regurgitation in 6 patients (22%) and severe in 3 (11%). Three patients (11%) underwent transcatheter valve-in-valve after their surgical pulmonary valve replacement. CONCLUSIONS: The early data regarding the Inspiris Resilia bioprosthesis use in the pulmonary position is concerning. The prosthesis design may not be suitable for low-pressure circulation, or modification of its implantation technique may be needed.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Said SM, Hiremath G, Aggarwal V, et al. Early Concerning Outcomes for the Edwards Inspiris Resilia Bioprosthesis in the Pulmonary Position. Ann Thorac Surg. 2022. PMID: 36174775. doi:10.1016/j.athoracsur.2022.09.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。